Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launch

Compass executives told BioPharma Dive that, if the FDA approves their treatment, they plan to follow the commercial strategy Johnson & Johnson used for its ketamine spray Spravato.

When Spravato entered the market seven years ago, few psychiatry clinics were equipped to deliver the therapy. J&J’s former Janssen president described the environment as underdeveloped and requiring a large investment in clinic infrastructure.

That investment appears to have paid off, as Spravato generated more than $1 billion in revenue in the first half of 2026 and helped spur the growth of thousands of interventional psychiatry clinics across the United States.

Compass Pathways, a UK‑based company, is developing COMP360, a synthetic psychedelic derived from mushroom compounds. The firm is gradually submitting its approval application to U.S. regulators and expects to complete the filing in the fourth quarter.

If approved, COMP360 could use the expanded network of specialized clinics that emerged from the Spravato rollout, potentially accelerating the entry of psychedelic therapies into the market.